ReviewCurrent opinion in HIV and AIDS2026
Hepatitis B virus vaccination in people with HIV: what's new?
Review in Current opinion in HIV and AIDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewDespite longstanding recommendations for HBV vaccination in people with HIV, coverage has remained low, and vaccine effectiveness has historically been limited due to poor immune responses and rapid waning of protection. This review summarizes recent advances in HBV vaccination strategies, updated guidelines, and emerging risks related to the increasing use of long-acting antiretroviral therapy and worsening vaccine mistrust. RECENT
findingsPeople with HIV experience reduced vaccine immunogenicity and faster waning of protective antibodies. The adjuvanted HepB-CpG vaccine, which includes a TLR-9 agonist, has demonstrated superior seroprotection and durability in both vaccine-naive and previously vaccinated individuals with HIV. Updated guidelines now recommend HepB-CpG as the preferred vaccine. The use of long-acting antiretroviral therapy and oral ART combinations without HBV activity has renewed attention to gaps in HBV immunity and the potential for new HBV infection or HBV reactivation. SUMMARY: HBV vaccination remains fundamental to HBV prevention in PWH, especially as antiretroviral strategies evolve. Broader use of HepB-CpG vaccine, attention to serologic monitoring, and proactive vaccination before antiretroviral switches are essential to reduce HBV-related morbidity and support HBV elimination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.